Raymond James & Associates Sells 5,138 Shares of Evolent Health, Inc. (NYSE:EVH)

Raymond James & Associates reduced its position in shares of Evolent Health, Inc. (NYSE:EVH) by 18.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,355 shares of the technology company’s stock after selling 5,138 shares during the quarter. Raymond James & Associates’ holdings in Evolent Health were worth $771,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in EVH. Nisa Investment Advisors LLC grew its position in shares of Evolent Health by 389.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock worth $137,000 after buying an additional 4,006 shares during the period. Teacher Retirement System of Texas raised its position in shares of Evolent Health by 9.0% during the 3rd quarter. Teacher Retirement System of Texas now owns 8,293 shares of the technology company’s stock valued at $226,000 after acquiring an additional 685 shares during the last quarter. Altshuler Shaham Ltd lifted its stake in shares of Evolent Health by 25.0% in the 3rd quarter. Altshuler Shaham Ltd now owns 15,000 shares of the technology company’s stock valued at $408,000 after purchasing an additional 3,000 shares during the period. Amalgamated Bank boosted its position in shares of Evolent Health by 9.7% in the 3rd quarter. Amalgamated Bank now owns 17,023 shares of the technology company’s stock worth $464,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Evolent Health during the third quarter worth $481,000.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on EVH shares. JMP Securities increased their target price on Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research note on Friday, February 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, March 15th. William Blair restated an “outperform” rating on shares of Evolent Health in a report on Tuesday, January 9th. Citigroup started coverage on shares of Evolent Health in a report on Monday. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Canaccord Genuity Group lowered their price objective on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, March 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Evolent Health Price Performance

Shares of NYSE EVH opened at $30.13 on Wednesday. Evolent Health, Inc. has a 1-year low of $23.33 and a 1-year high of $36.70. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a fifty day moving average price of $31.93 and a 200 day moving average price of $30.29. The firm has a market cap of $3.48 billion, a PE ratio of -23.72 and a beta of 1.54.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. The firm had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. Research analysts predict that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.